JO3659B1 - أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية - Google Patents

أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية

Info

Publication number
JO3659B1
JO3659B1 JOP/2011/0179A JOP20110179A JO3659B1 JO 3659 B1 JO3659 B1 JO 3659B1 JO P20110179 A JOP20110179 A JO P20110179A JO 3659 B1 JO3659 B1 JO 3659B1
Authority
JO
Jordan
Prior art keywords
pharmaceutically acceptable
dose
bendamustine
active ingredient
derivative
Prior art date
Application number
JOP/2011/0179A
Other languages
English (en)
Inventor
Taoufik Ouatas
Ulrich Patzak
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44261747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3659(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Application granted granted Critical
Publication of JO3659B1 publication Critical patent/JO3659B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع بتوفير تركيبة صيدلانية للإعطاء عن طريق الفم والتي تشتمل على بنداموستين أو إستر أو ملح مقبول صيدلانياً أو ذوابة منها في شكل مكون فعال وسواغ مقبول صيدلانياً والذي يعرض تحلل لبنداموستين من 60% على الأقل في 20 دقيقة، 70% في 40 دقيقة و80% في 60 دقيقة كما تم قياس ذلك باستخدام جهاز بمحراك للسوائل عند 50 لفة في الدقيقة طبقاً لـ European Pharmacopoeia في 500 مل من وسط الذوبان عند رقم هيدروجيني يصل إلى 1.5، وحيث أن السواغ المقبول صيدلانياً يكون إما مادة خافضة للتوتر السطحي غير أيونية تم اختيارها من مجموعة تتكون من زيت خروع تمت معالجته ببولي إيثوكسي أو مشتق منه وبوليمر إغلاق مشترك من أكسيد الإيثيلين وأكسيد البروبيلين أو سكاريد مقبول صيدلانياً منه تم اختياره من مجموعة تتكون من واحد أو أكثر من السكاريد الأحادي أو السكاريد الثنائي أوليجيو سكاريد أو أوليجيو سكاريد حلقي أو بولي سكاريد وسكاريد من الكحول حيث تكون النسبة بالوزن من المكون الفعال إلى سواغ (سواغات) السكاريد في مدى من 1: 1-5. يتعلق الاختراع أيضاً بالصيغة الصيدلانية السابقة التي يتم استخدامها للإعطاء عن طريق الفم لمعالجة حالة طبية يتم اختيارها من سرطان الدم اللمفاوي المزمن، سرطان الدم اللمفاوي الحاد، الورم السرطاني النخاعي المزمن وسرطان الدم النخاعي الحاد، ومرض هودجكن، والورم اللمفاوي خلاف هودجكن، الورم النخاعي المتعدد، سرطان الثدي، وسرطان المبيض وسرطان الرئة ذات الخلايا الصغيرة وسرطان الرئة ذات الخلايا غير الصغيرة. يتعلق الاختراع أيضاً بالتركيبة السابقة المستخدمة في نظام الجرعة المشتملة على الأقل على إعطاء جرعة من 100 إلى 600 مجم/م2/الشخص من بنداميوستين في اليوم رقم 1 واليوم رقم 2 وبشكل اختياري جرعة من 50 إلى 150 مجم/م2 عن طريق الوريد أو عن طريق الفم من كورتيكوستيرويد في الأيام من 1 إلى 5 وبشكل اختياري تكون جرعة مناسبة من المكون الفعال تم اختيارها من مجموعة تتكون من الجسم المضاد الخاص بـ CD20 ومشتق أنثراسيكلين وفينيكا قلوي أو مشتق بلاتين وتكرار نظام المعالجة لنظام الجرعة المذكور من 4 إلى 15 مرة بعد فواصل زمنية تصل من اثنين إلى أربعة أسابيع.
JOP/2011/0179A 2010-06-02 2011-05-31 أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية JO3659B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10005762 2010-06-02
EP11075046 2011-03-14

Publications (1)

Publication Number Publication Date
JO3659B1 true JO3659B1 (ar) 2020-08-27

Family

ID=44261747

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0179A JO3659B1 (ar) 2010-06-02 2011-05-31 أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية

Country Status (26)

Country Link
US (2) US20130209558A1 (ar)
EP (1) EP2575785B1 (ar)
JP (2) JP2013527206A (ar)
KR (1) KR101830147B1 (ar)
CN (1) CN103037852B (ar)
AR (1) AR081575A1 (ar)
AU (1) AU2011260614B2 (ar)
BR (1) BR112012030658B1 (ar)
CA (1) CA2800277A1 (ar)
CL (1) CL2012003340A1 (ar)
CO (1) CO6640268A2 (ar)
DK (1) DK2575785T3 (ar)
EA (1) EA027786B1 (ar)
ES (1) ES2935792T3 (ar)
FI (1) FI2575785T3 (ar)
IL (2) IL223309B (ar)
JO (1) JO3659B1 (ar)
MX (1) MX2012013873A (ar)
MY (1) MY173881A (ar)
NZ (1) NZ603874A (ar)
PH (1) PH12012502282B1 (ar)
PL (1) PL2575785T3 (ar)
SG (1) SG185794A1 (ar)
TW (1) TWI556819B (ar)
WO (1) WO2011151086A1 (ar)
ZA (1) ZA201208822B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103826630B (zh) * 2011-09-18 2016-12-07 杭州民生药物研究院有限公司 药物组合物
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica
EP2942052A4 (en) * 2013-01-07 2016-06-08 Sam A Pharm Co Ltd NEW FORMULATION OF RAPID DISSOLUTION PELLETS WITH ENHANCED SOLUBILITY
CN105491886B (zh) * 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CN110772480B (zh) * 2016-03-25 2022-05-17 南京百劲企业管理咨询有限公司 苯达莫司汀药剂组合物及应用
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
WO2020128913A1 (en) 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating multiple myeloma
CN112848583B (zh) * 2020-12-31 2022-08-05 雅达环保科技(玉田)有限公司 一种阻燃保温板及其制备方法
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (ar) * 1903-10-08 1905-03-16
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
DE19826517B4 (de) * 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
JP2006514119A (ja) * 2003-02-12 2006-04-27 アール アンド ピー コリア カンパニー リミテッド 溶解率が向上した難溶性薬剤の溶媒系
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
CN101933923A (zh) * 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA2682752C (en) * 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
MX2010000465A (es) 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
US20100209927A1 (en) * 2007-11-06 2010-08-19 Menon Vinod P Processing device tablet
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2299987B1 (en) * 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
UA102120C2 (ru) * 2008-12-03 2013-06-10 Астеллас Дойчленд Гмбх Пероральная форма дозирования бендамустина
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク． ベンダムスチンの経口製剤
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter

Also Published As

Publication number Publication date
KR101830147B1 (ko) 2018-02-20
US20130209558A1 (en) 2013-08-15
JP2013527206A (ja) 2013-06-27
US10485787B2 (en) 2019-11-26
AR081575A1 (es) 2012-10-03
EA201291249A1 (ru) 2014-07-30
AU2011260614A1 (en) 2013-01-10
MY173881A (en) 2020-02-26
TWI556819B (zh) 2016-11-11
EP2575785B1 (en) 2022-10-26
ES2935792T3 (es) 2023-03-10
JP6259490B2 (ja) 2018-01-10
BR112012030658B1 (pt) 2022-08-02
MX2012013873A (es) 2013-07-03
CO6640268A2 (es) 2013-03-22
CN103037852B (zh) 2016-06-15
DK2575785T3 (da) 2023-01-30
PL2575785T3 (pl) 2023-02-20
EA027786B1 (ru) 2017-09-29
IL223309A0 (en) 2013-02-03
EP2575785A1 (en) 2013-04-10
KR20130116164A (ko) 2013-10-23
TW201210591A (en) 2012-03-16
IL272501A (en) 2020-03-31
BR112012030658A2 (pt) 2016-08-16
PH12012502282A1 (en) 2013-02-11
CL2012003340A1 (es) 2014-03-28
WO2011151086A1 (en) 2011-12-08
NZ603874A (en) 2014-08-29
SG185794A1 (en) 2013-01-30
US20150258070A1 (en) 2015-09-17
PH12012502282B1 (en) 2019-06-14
AU2011260614B2 (en) 2016-12-15
FI2575785T3 (fi) 2023-01-31
IL223309B (en) 2020-05-31
ZA201208822B (en) 2014-08-27
JP2016172763A (ja) 2016-09-29
CN103037852A (zh) 2013-04-10
CA2800277A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
PH12012502282B1 (en) Oral dosage forms of bendamustine and therapeutic use thereof
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
TWI791467B (zh) 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）、奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）、５-氟尿嘧啶及甲醯四氫葉酸（ｌｅｕｃｏｖｏｒｉｎ）之組合療法治療胃癌
CN106822905B (zh) 含Survivin抑制剂和IRE1抑制剂的药物及用途
ME02520B (me) Farmaceutske kompozicije
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
McCarthy et al. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer
CN105338973A (zh) 使用辅酶q10联合疗法治疗癌症
JP2012510484A5 (ar)
WO2014160216A3 (en) Dual targeting anticancer agents
KR20160135230A (ko) 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도
CN102526731B (zh) 一种含有牛蒡苷元的药物组合物
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
RU2011129815A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
CN105380956A (zh) 一种治疗白血病的含艾德拉尼的药物组合物及应用
US8663711B2 (en) Use of armillaridin for treating cancer
CN102781238A (zh) Tivozanib和坦罗莫司的组合
Sahu et al. mucormycosis in indian covid-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics 2021; 10
JP2016104703A (ja) 抗腫瘍剤
Gelb et al. Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study
CN111110678A (zh) 一种含克唑替尼与山奈酚药物组合物及其应用
RU2014125702A (ru) Фармацевтическая композиция для профилактики или лечения гиперлипидемии
JP2025516925A (ja) 再発がんを前治療する方法
JP2016527284A5 (ar)
WO2021224381A1 (en) Combination therapy for treating cancer